Funding agencies: This work was supported by the Centre of reference of Huntington's disease (Ministry of Health, France) and by a Contrat d'interface INSERM (ACBL). Additional support was provided through the NeurATRIS (European Advanced Translational Research Infrastructure in Neurosciences) project, the Groupement d'Intérêt Scientifique (GIS)-Institut des Maladies Rares and the” Biomarker program” AP-HP.
Unified Huntington's disease rating scale for advanced patients: Validation and follow-up study
Version of Record online: 25 OCT 2013
© 2013 Movement Disorder Society
Volume 28, Issue 12, pages 1717–1723, October 2013
How to Cite
Youssov, K., Dolbeau, G., Maison, P., Boissé, M.-F., de Langavant, L. C., Roos, R. A.C. and Bachoud-Lévi, A.-C. (2013), Unified Huntington's disease rating scale for advanced patients: Validation and follow-up study. Mov. Disord., 28: 1717–1723. doi: 10.1002/mds.25654
Relevant conflicts of interest/financial disclosures: Dr Maison reports support for eusapharma for analysing the RHLF cohort. Dr Roos receives project grants from CHDI and the Gossweiler Foundation. Dr Bachoud-Lévi serves as an expert for the University of Sacramento, and receives institutional support from the Ministry of Health for the management of the Centre of reference for Huntington's disease. She benefits from a “Contrat d'interface” by the INSERM for conducting her research and a contract with CHDI for Registry.
- Issue online: 25 OCT 2013
- Version of Record online: 25 OCT 2013
- Manuscript Accepted: 29 JUL 2013
- Manuscript Revised: 25 JUL 2013
- Manuscript Received: 6 NOV 2012
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.